A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis

Trial Profile

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of GMI-1070, A Pan-Selectin Inhibitor, In Subjects Hospitalized For Sickle Cell Vaso-Occlusive Crisis

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Mar 2015

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Sickle cell anaemia
  • Focus Therapeutic Use
  • Sponsors GlycoMimetics; Pfizer
  • Most Recent Events

    • 03 Mar 2015 According to GlycoMimetics media release, results were published in Blood.
    • 03 Mar 2015 Results published in the Media Release.
    • 10 Dec 2013 Results for the paediatric subgroup presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top